Steatosis is recognized as a cofactor influencing the presence and progression of fibrosis in chronic hepatitis C. It has been reported that antiviral therapy may reduce the progression of fibrosis and leads to regression in chronic hepatitis C patients achieving a sustained virological response (SVR). Whether steatosis might affect the long-term histological outcome of antiviral therapy remains unclear.
Methods
One-hundred and sixty-one consecutive patients (genotype 1, n=76; genotype 2, n=73) receiving interferon-α2b and ribavirin were analysed. Ninety patients had paired biopsies with a mean interval of 29.1 ±7.1 months.
Results
Variables associated with baseline steatosis were higher body mass index (≥25, P=0.002) and higher fibrosis stage (≥2, P=0.019). Neither the presence nor the severity of steatosis was associated with SVR. Evaluation of paired biopsies showed no different distribution of steatosis evolution between patients with and without SVR (P=0.374). Among patients achieving a SVR, there was a significant difference in fibrosis changes between those with grade 0 or 1 steatosis and with grade 2 or 3 steatosis at post-treatment biopsy (-0.6 ±1.2 vs 0.3 ±1.3, P=0.041), whereas changes in histological activity index did not differ (-3.7 ±2.6 vs -4.0 ±2.9, P=0.740). Stepwise logistic regression analysis showed that SVR (odds ratio [OR]: 16.33, P=0.004) and grade 0 or 1 post-treatment steatosis (OR: 12.82, P=0.018) were independently associated with fibrosis regression.
Conclusions
In patients with chronic hepatitis C, steatosis not only correlates with advanced fibrosis at baseline but also affects fibrosis regression after antiviral therapy.
References
1.
AlterM.J.Epidemiology of hepatitis C in the West.Semin Liver Dis1995; 15: 5–14.
2.
SeeffL.B., Buskell-BalesZ., WrightE.C.Long-term mortality after transfusion-associated non-A, non-B hepatitis. The Natl Heart, Lung, Blood Inst Study GroupN Engl J Med1992; 327: 1906–1911.
3.
LeeC.M., LuS.N., ChangchienC.S.Age, gender, and local geographic variations of viral etiology of hepatocel-lular carcinoma in a hyperendemic area for hepatitis B virus infection.Cancer1999; 86: 1143–1150.
4.
NiederauC., LangeS., HeintgesT.Prognosis of chronic hepatitis C: results of a large, prospective cohort study.Hepatology1998; 28: 1687–1695.
5.
ChiaramonteM., StroffoliniT., VianA.Rate of incidence of hepatocellular carcinoma in patients with compensated viral cirrhosis.Cancer1999; 85: 2132–2137.
6.
ChanderG., SulkowskiM.S., JenckesM.W.Treatment of chronic hepatitis C: a systematic review.Hepatology2002; 36 (5 Suppl 1): 135–144.
7.
MannsM.P., McHutchisonJ.G., GordonS.C.Peginterferon alfa-2b plus ribavirin compared with inter-feron alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial.Lancet2001; 358: 958–965.
8.
FriedM.W., ShiffmanM.L., ReddyK.R.Peginterferon alpha-2a plus ribavirin for chronic hepatitis C virus infection.N Engl J Med2002; 347: 975–982.
9.
HadziyannisS.J., SetteH.Jr., MorganT.R.Peginterferon-α2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose.Ann Intern Med2004; 140: 346–355.
10.
PoynardT., RatziuV., McHutchisonJ.Effect of treatment with peg-interferon or interferon alfa-2b and ribavirin on steatosis in patients infected with hepatitis C.Hepatology2003; 38: 75–85.
11.
PattonH.M., PatelK., BehlingC.The impact of steatosis on disease progression and early and sustained treatment response in chronic hepatitis C patients.J Hepatol2004; 40: 484–90.
12.
ThomopoulosK.C., TheocharisG.J., TsamantasA.C.Liver steatosis is an independent risk factor for treatment failure in patients with chronic hepatitis C.Eur J Gastroenterol Hepatol2005; 17: 149–153.
13.
AkutaN., SuzukiF., SuzukiY.Hepatocyte steatosis is an important predictor of response to interferon (IFN) monotherapy in Japanese patients infected with HCV genotype 2a: Virological features of IFN-resistant cases with hepatocyte steatosis.J Med Virol2005; 75: 550–558.
14.
BresslerB.L., GuindiM., TomlinsonG., HeathcoteJ.High body mass index is an independent risk factor for nonresponse to antiviral treatment in chronic hepatitis CHepatology2003; 38: 639–644.
15.
FabrisP., FloreaniA., CarlottoA.Impact of liver steatosis on virological response in elderly Italian patients with chronic hepatitis C treated with peg-interferon alpha-2b plus ribavirin.Aliment Pharmacol Ther2005; 21: 1173–1178.
16.
LiuC.J., JengY.M., ChenP.J.Influence of metabolic syndrome, viral genotype and antiviral therapy on superimposed fatty liver disease in chronic hepatitis C.Antivir Ther2005; 10: 405–415.
17.
YounossiZ.M., McCulloughA.J., OngJ.P.Obesity and non-alcoholic fatty liver disease in chronic hepatitis C.J Clin Gastroenterol. 2004; 38: 705–709.
18.
Romero-GomezM., Del Mar ViloriaM., AndradeR.J.Insulin resistance impairs sustained response rate to peginterferon plus ribavirin in chronic hepatitis C patients.Gastroenterology2005; 128: 636–641.
19.
HouriganL.F., MacdonaldG.A., PurdieD.Fibrosis in chronic hepatitis C correlates significantly with body mass index and steatosis.Hepatology1999; 29: 1215–1219.
20.
HuK.Q., KyuloN.L., EsrailianE.Overweight and obesity, hepatic steatosis, and progression of chronic hepatitis C: a retrospective study on a large cohort of patients in the United States.J Hepatol2004; 40: 147–154.
21.
CasteraL., HezodeC., Roudot-thoravalF.Worsening of steatosis is an independent factor of fibrosis progression in untreated patients with chronic hepatitis C and paired liver biopsies.Gut2003; 52: 288–292.
22.
ShiratoriY., ImazekiF., MoriyamaM.Histologic improvement of fibrosis in patients with hepatitis C who have sustained response to interferon therapy.Ann Intern Med. 2000; 132: 517–524.
23.
OmataM., YoshidaH.Resolution of liver cirrhosis and prevention of hepatocellular carcinoma by interferon therapy against chronic hepatitis C.Scand J Gastroenterol Suppl. 2003; 237: 47–51.
24.
PoynardT., McHutchisonJ., DavisG.L.Impact of interferon alfa-2b and ribavirin on progression of liver fibrosis in patients with chronic hepatitis C.Hepatology2000; 32: 1131–1137.
25.
CasteraL., HezodeC., Roudot-ThoravalF.Effect of antiviral treatment on evolution of liver steatosis in patients with chronic hepatitis C: indirect evidence of a role of hepatitis C virus genotype 3 in steatosis.Gut2004; 53: 420–424.
26.
MarcellinP., AsselahT., BoyerN.Fibrosis and disease progression in hepatitis C.Hepatology2002; 36 (5 Suppl 1): S47–56.
27.
Which classification for chronic hepatitis? Lessons from the hepatitis C virus.Groupe METAVIR.Gastroenterol Clin Biol1994; 18: 403–406.
28.
Intraobserver and interobserver variations in liver biopsy interpretation in patients with chronic hepatitis C.The French METAVIR Cooperative Study Group.Hepatology1994; 20: 15–20.
29.
DesmetV.J., GerberM., HoofnagleJ.H., MannsM., ScheuerP.J.Classification of chronic hepatitis: diagnosis, grading and staging.Hepatology1994; 19: 1513–1520.
30.
PoynardT., BedossaP., OpolonP.Natural history of liver fibrosis progression in patients with chronic hepatitis C. The OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups.Lancet1997; 349: 825–832.
31.
WrightM., GoldinR., FabreA.; HENCORE collaboration. Measurement and determinants of the natural history of liver fibrosis in hepatitis C virus infection: a cross sectional and longitudinal study.Gut2003; 52: 574–579.
32.
Rubbia-BrandtL., FabrisP., PaganinS.Steatosis affects chronic hepatitis C progression in a genotype specific way.Gut2004; 53: 406–412.
33.
HezodeC., Roudot-ThoravalF., ZafraniE.S., DhumeauxD., PawlotskyJ.M.Different mechanisms of steatosis in hepatitis C virus genotypes 1 and 3 infections.J Viral Hepat2004; 11: 455–458.
34.
HickmanI.J., CloustonA.D., MacdonaldG.A.Effect of weight reduction on liver histology and biochemistry in patients with chronic hepatitis C.Gut2002; 51: 89–94.
